Effect of Paricalcitol on Markers of Inflammation in Hemodialysis Patients
Kidney Failure
About this trial
This is an interventional prevention trial for Kidney Failure focused on measuring End Stage Renal Disease, Inflammation
Eligibility Criteria
Inclusion Criteria: CKD and receiving hemodialysis for greater than or equal to 3 months Age greater than or equal to 18 years Medically stable AVF or PTFE dialysis access No acute inflammatory disease within 4 weeks prior to study On an average dose of 3 - 7 mcg of paricalcitol three times per week for 4 weeks prior to the study Two consecutive iPTH of 150-400 (biPTH 75 - 200) =/- 30% one week apart Ca <10.2 mg/dL; PO4 <7.0 Kt/V greater than or equal to 1.2 On no other interventional drugs/devices in the past 30 days Exclusion Criteria: Currently receiving dialysis using a venous catheter access Currently receiving high dose immunosuppressive therapy (greater than or equal to 10 mg prednisone) Pregnancy Hospitalization within the last 4 weeks. -
Sites / Locations
- Southwest Nephrology
- Nephrology Center
- Nephrology Associates P.A.
- Delaware Valley Nephrology
- Nephrology Associates, PC
- Tyler Nephrology Associates
Arms of the Study
Arm 1
Arm 2
Active Comparator
No Intervention
A
B
Receive Paricalcitol
Paricalcitol on hold